《骨质疏松症临床治疗生物制剂循证用药指南》推荐意见外审：一项横断面调查

打开文本图片集

中图分类号R969.3 文献标志码A 文章编号 1001-0408（2025）09-1025-05

DOI 10.6039/j.issn.1001-0408.2025.09.01

ABSTRACT OBJECTIVE To assess the scientific rigor， clarityandfeasibilityoftherecommendationsofthe GuidelinesforEvidence-basedUseofBiological Agentsforthe Clinical TreatmentofOsteoporosis（hereinafterreferredtoas theGuideline）through external review，in order to further revise andimprovetheGuidelinerecommendations. METHODS This study employed a cross-sectional survey research design，a convenience sampling method was adopted

toselectfrontlinemedicalworkersinthefieldfosteoporosis（includingclnicaldoctors，iicalpharmacistsandurses）aswel aspatientsortheirfamilymembers.Externalreviewwasconductedthroughacombinationofclosed-endedandopen-ended electronicquestionnairestogetfeedbackfromthemontheappreciation，clarityandfeasibilityofthe32preliminary recommendationsintheGuideline.RESULTSAtotalof90externalreviewsubjetsfrom15hospitalswerecollected，including45 clinicaldoctors，15clinicalpharmacists，15nursesand15patientsortheirfamilymembers.Theoverallappreciationdegreeof recommendations was 9 9 . 3 8 % ，the overall clarity degree of recommendationswas 9 8 . 9 2 % ，and the overall feasibility degree of recommendations was 9 9 . 6 5 % . At the same time，111 subjective suggestions were collected，which provided an important reference forthefurtherimprovementoftheGuidelinerecommendations.Basedontheabovefedback，theGuidelinesteeringcommiteeand coreexpert grouprevisedthewordingof12draftrecommendationswithout deletion，andfinallydetermined32recommendations. CONCLUSIONSTheexternalreviewprovidesanimportantbasis forthefinalformationof theGuideline，furtherimproves the scientificrigorlarityandfeasibityofthecommendations，ndesuresthestandardization，practicalityandimplementabilityof the Guideline.

KEYWORDSosteoporosis；biological agent；evidence-based medication guideline；external review；recommendations

临床实践指南是医学领域的重要指导性文件，其基于当前可获得的最佳证据，为临床提供科学、权威且规范的治疗建议。（剩余7668字）